Fighting Obesity with a Sugar-Based Library: Discovery of Novel MCH-1R Antagonists by a New Computational-VAST Approach for Exploration of GPCR Binding Sites

Alexander Heifetz,^{1*} Oliver Barker,¹ Geraldine Verquin,² Norbert Wimmer,² Wim Meutermans,² Sandeep Pal,¹ Richard J. Law,¹ Mark Whittaker¹

¹ Evotec (UK) Ltd., 114 Milton Park, Abingdon, Oxfordshire OX14 4SA, United

Kingdom;

² Alchemia Ltd, Eight Mile Plains, Queensland 4113, Australia

*Corresponding author. Tel.: +44 (0)1235 83 89 25; Fax: +44 (0)1235 86 31 39

E-Mail address: Alexander.Heifetz@Evotec.com

SUPPLEMENTARY METHODS

Calculation of AMBER MCH-1R-ligand interaction energy

The MM_PBSA/GBSA approach ¹ is post-processing method to evaluate free energies of binding between protein and ligand. The all-atom AMBER molecular mechanics force field ¹⁻³ was used to calculate interactions energy^{1,4} between MCH-1R and ligand. The calculations of interaction energy were performed using ANAL program of AMBER 8 (2004) molecular simulation package and represent the internal energy (bond, angle and dihedral), and van der Waals and electrostatic interactions. The MM_PBSA script calculates the energies of the complex and of all interacting components and deducts them from each other to obtain free energies of binding. The MM_PBSA/GBSA method combines the molecular mechanical energies with continuum solvent approaches. The MM_PBSA/GBSA approach has been successfully applied to study protein-ligand complexes ⁵.

Shape comparison method

The shape comparison and scoring was performed using the OMEGA-ROCS tool as implemented in the OpenEye software package (version 3.0.0)⁶. Prior to shape comparison, we used OMEGA to generate potential bioactive and energetically accessible conformations for each molecule. A Gaussian description of molecular shape is used to compare the shapes of two molecules by maximization of their volume intersection ⁶. ROCS - is a shape-based superposition method. Molecules are superposed by a solid-body optimization process that maximizes the overlap volume between them. Volume overlap is not the hard-sphere overlap volume, but rather a Gaussian-based overlap parameterized to reproduce hard-sphere volumes.


ROCS uses only the heavy atoms of a ligand, hydrogens are ignored. Since shape and volume in this context are so closely related, a volume overlap maximization procedure is an excellent method for gaining insights into similar shapes.

Statistical comparison of sub-pocket occupancy effects


For comparison of the effect of individual sub-pocket occupancy on antagonist activity we performed Welch's *t*-test (Welch,B.L.⁷ The generalization of "Student's" problem when several different population variances are involved). This test can be used to estimate the significance of differences in activity between two groups (i.e. where one group of compounds occupies a given pocket, and the other does not). This particular test was chosen as neither the number of members of each group, nor the variance of activities within each group need be the same. Calculations were performed online using GraphPad [http://www.graphpad.com/quickcalcs/ttest1.cfm] server.

Supplementary Figure S1: Shows multiple amino-acid sequence alignment of MCH-1R aligned with four GPCR crystal structures [human dopamine D3 receptor (D3, PDB entry 3PBL), β 2-adrenergic receptor (β 2AR, PDB entry 2RH1), human A2A adenosine receptor (A2A, PDB entry 3EML) and bovine rhodopsin (PDB entry 1U19)], the colour coding for TM 1 to 7 is dark orange, pink, red, purple, dark red, orange and light yellow respectively, the similarity or dissimilarity of each amino-acid compare to MCH-1R is shown by the bar, the strength of similarity are represented by the spectrum from blue (max similarity) to red (max dissimilarity), bar length and its directionality (up – similarity, down dissimilarity)

Similarity	5 10 15 20 25 30 35 40 45 50
MCH-1R:1	GSISYINIIMPSVFGTIČLLGIIGNSTVIFAVVKKSKLHWCNNVPDIFIINLS
1U19:2	_GSTSYTNTTMPSVFGTTCLLGTTGNSTVTFAVVKKSKLHWCNNVPDTFTTNLS _LAE <mark>PŴQF</mark> SMĽĄAYMFLLIMĽGFPIŇFLTLŸVTVQHKKLR TPLNYŤLLNLÄ
3EML:3	10 15 20 25 30 35 40 45
2RH1:4	SVYĨTVELÄTAVLÄTLGNŸLVCWÄVWLNŜNLQ····NŸTNYFŸVSLA _QRDË <mark>VWVVĞMGTV</mark> ÄSLTVLATVFĞNVLVĨTATĄŘ <mark>F</mark> ERLQ····TVTŅŸFTTSLA
3PBL:5	
	<u>58 63 68 73 78 83 88 93 98 103</u>
Similarity	
MCH-1R:1	_VVDLLFLLGMPFMIHQLMGNG VWHFGETMCTLITAMDANSQFTSTYILTAMA
1019:2	<u>_</u> WADLFMVFGĞETTTL¥TSLHG`YEVF <mark>G</mark> PTGÖNLEGFFATLĞGELAĽWSLVVLA
3EML:3 2RH1:4	_VADLFMVFGGFTTTLYTSLHG·YFVF@PTOCNLEGFFATLGGEIALWSLVVLA _AADIAVGVLATPFAITISTG···FCAACHGCLFIACFVLVLTQSSIFSLLAIA _CAQLVMGLAVVPEGAAHJLMK·MWTFGNFWCEEWTSIDVLCVTASIETLCVIA
3PBL:5	<u> </u>
JFBL.J	_VAĎLLVAŤLVMPŴVVYLËVTGGŸWNFS <mark>ŘICCDŸFVTLĎVMMCTASIWNLCAIŠ</mark>
	414 446 424 426 424 426 444 446 466 466
Similarity	
MCH-1R:1	200 235 240 IDRYLAT HP ··· ISSTKFRK PSVATLVICL WALSFISITE ··· VWLYARL 128 144 200 155 151 TT ··· VWLYARL
1U19:2	
3EML:3	
2RH1:4	<u></u>
3PBL:5	
Similarity	164 169 174 179 184 189 194 199 204 209
Similarity	
MCH-1R:1	IPFPGGAVGCGIRLPNPDTDLWFTLYQFFLAFALPFVVITAAYVRTLQ
MCH-1R:1 1U19:2	IPEPGGÄVGCGIRLPNPDTDLYWFTLYQFFLAFALPFVVITAAVVRILQ IPEGMQCSCGIDYYTPHEETNNESFVIYMFVVHFIIPLIVITECYGQLVF
MCH-1R:1	IPFPGGÄVGCGÜRLPNPDTDLŸVETLYGFFLAFALPFVVITAAYVRIDQ IPEGMOCSCGIDYYTPHEETNNESFVIYMFIIPLIVIFEOYGOLYF KEGKNHSQGCGEGQVACLEEDVVIMMYMYYFNFFACVLYPLLMLGVYLRTFL
MCH-1R:1 1U19:2 3EML:3	LEFPGGAVGCGIRLPNPDTLIVVETLYQFFLAFALPFVVITAAYVRTLQ IPEGMQCSCGIDYYTPHEETNNESFVVITAFIIPLIVIFFCYGQLYF KEGKNHSQGCGEGQVACLEEDVVPMNYMYYFNFFACVLYPLLLMLGVYLRTFL RATHQEAINCYAEETCCDFFTNQAYALASSIYSFYVELVIMVFVYSRVFQ
MCH-1R:1 1U19:2 3EML:3 2RH1:4	IPFPGGÄVGCGÜRLPNPDTDLŸVETLYGFFLAFALPFVVITAAYVRIDQ IPEGMOCSCGIDYYTPHEETNNESFVIYMFIIPLIVIFEOYGOLYF KEGKNHSQGCGEGQVACLEEDVVIMMYMYYFNFFACVLYPLLMLGVYLRTFL
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5	LEFPGGAVGCGIRLPNPDTLIVVETLYQFFLAFALPFVVITAAYVRTLQ IPEGMQCSCGIDYYTPHEETNNESFVVITAFIIPLIVIFFCYGQLYF KEGKNHSQGCGEGQVACLEEDVVPMNYMYYFNFFACVLYPLLLMLGVYLRTFL RATHQEAINCYAEETCCDFFTNQAYALASSIYSFYVELVIMVFVYSRVFQ
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity	1200 PPGGÃVGCGI RLPNPDTDLYWETLYGFFLAFALPEVVI TAAYVRILQ IPEGMQCSCGI DIYYTPHEETNESEVI YGFFLAFALPEVVI TAAYVRILQ IPEGMQCSCGEGQVACLFEDVVPMNYMYTFNFACVLYPILLMLGVYLRIFL RATHQEAINCEAEETCCDFFTNOAYALASSI VSFYVPLVIMVFVVSRVFQ NTTGDPTVCSISNPDEVIYSSVVSFYLPEQVTVIVYARIYV
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1	1200 PPGGÃVGCGI RLPNPDTDLYWETLYGFFLAFALPEVVI TAAYVRILQ IPEGMQCSCGI DIYYTPHEETNESEVI YGFFLAFALPEVVI TAAYVRILQ IPEGMQCSCGEGQVACLFEDVVPMNYMYTFNFACVLYPILLMLGVYLRIFL RATHQEAINCEAEETCCDFFTNOAYALASSI VSFYVPLVIMVFVVSRVFQ NTTGDPTVCSISNPDEVIYSSVVSFYLPEQVTVIVYARIYV
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2	1297 197
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2 3EML:3	1297 197
MCH-1R1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R1 1U19:2 3EML:3 2RH1:4	1000000000000000000000000000000000000
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2 3EML:3	1297 197
MCH-1R1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R1 1U19:2 3EML:3 2RH1:4	1200 1200
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5	1000000000000000000000000000000000000
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1	1000000000000000000000000000000000000
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2	1000000000000000000000000000000000000
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2 3EML:3 Similarity MCH-1R:1 1U19:2 3EML:3	1000000000000000000000000000000000000
MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2 3EML:3 2RH1:4 3PBL:5 Similarity MCH-1R:1 1U19:2	1200 1200



Supplementary Table S1: Representative set of known 32 potent MCH-1R antagonists



Reference

- Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E., III Acc. Chem Res. 2000, 33 (12), 889-897.
- 2. Yang, L.; Tan, C. H.; Hsieh, M. J.; Wang, J.; Duan, Y.; Cieplak, P.; Caldwell, J.; Kollman, P. A.; Luo, R. *J. Phys. Chem B* **2006**, *110* (26), 13166-13176.
- 3. Kollman, P.; Van Gunsteren, W. F. *Methods Enzymol.* **1987**, *154*, 430-449.
- 4. Wang, J.; Morin, P.; Wang, W.; Kollman, P. A. *J. Am. Chem Soc.* **2001**, *123* (22), 5221-5230.
- 5. Massova, I.; Kollman, P. A. J. Comput. Chem 2002, 23 (16), 1559-1576.
- 6. Grant, J. A.; Pickup, B. T.; Sykes, M. J.; Kitchen, C. A.; Nicholls, A. *Phys. Chem Chem Phys.* **2007**, *9* (35), 4913-4922.
- 7. Welch, B. L. Biometrika 1947, 34, 28-35.